Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

Core Insights - Allogene Therapeutics is advancing its allogeneic CAR T (AlloCAR T) products for cancer and autoimmune diseases, with two abstracts published ahead of the 2025 ASCO Annual Meeting [1][9] Group 1: ALLO-316 Development - ALLO-316 is an investigational AlloCAR T product targeting CD70, currently studied in patients with advanced or metastatic renal cell carcinoma (RCC) [2][7] - The Phase 1 TRAVERSE study will present updated data, focusing on a cohort treated with a regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million CAR T cells [2][4] - ALLO-316 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, highlighting its potential to address unmet needs in advanced or metastatic CD70+ RCC [7] Group 2: ALPHA3 Trial Overview - The ongoing pivotal Phase 2 ALPHA3 trial evaluates cemacabtagene ansegedleucel (cema-cel) as a first-line consolidation strategy for patients with large B-cell lymphoma (LBCL) who are minimal residual disease (MRD) positive after initial treatment [3][5] - The ALPHA3 trial aims to provide a one-time, "off-the-shelf" treatment option that can be administered immediately upon MRD detection, potentially becoming the standard "7th cycle" of frontline treatment [8] Group 3: Market Context and Company Positioning - Over 60,000 patients are expected to be treated for LBCL annually in the US, EU, and UK, with approximately 30% of patients relapsing after initial treatment [8] - Allogene Therapeutics is focused on developing a pipeline of readily available CAR T cell product candidates, aiming to deliver cell therapy on-demand and at greater scale [9]